RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures
全國合作伙伴推出初步Venowave銷售計劃,以評估醫療保險/醫療補助的報銷時間和計費程序。
Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value
初步計劃取得成功後,經銷商承諾收購剩餘庫存,總計價值238萬美元的報銷金額。
Toronto, Ontario--(Newsfile Corp. - August 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is proud to announce the addition of a new Nationwide U.S. Durable Medical Equipment (DME) distribution partner that has launched an initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures. Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value. The new partner's name will be disclosed in future upcoming releases, following initial program success.
多倫多,安大略省--(新聞稿公司-2024年8月23日)- Therma Bright Inc(TSXV: THRM)(OTCQB: TBRIF)(FSE: JNX)(以下簡稱"Therma"或"公司"),一家在各種尖端專有診斷和醫療器械技術方面進行開發和投資合作的創業公司,自豪地宣佈與一家新的全美耐用醫療器械(DME)分銷合作伙伴合作,該合作伙伴推出了一項初步Venowave銷售計劃,以評估醫療保險/醫療補助的報銷時間和計費程序。初步計劃取得成功後,經銷商承諾收購剩餘庫存,總計價值238萬美元的報銷金額。合作伙伴的名稱將在未來的發佈中披露,以說明初步計劃的成功。
With strong distribution network interest, Therma Bright expects its current inventory of 2,000 units-representing up to USD $2.38 million in reimbursement value-to be quickly sold with strong demand for additional orders. The device, effective for ten (10) circulatory indications, offers up to USD $1,199 reimbursement, which will significantly contribute to the Company's revenue and pave the way for sustained growth and enhanced marketplace valuation.
在強大的分銷網絡興趣下,Therma Bright預計其目前的2,000套庫存(代表238萬美元的報銷價值)將很快銷售完畢,對額外訂單的需求很旺盛。該設備適用於10個血液循環適應症,可獲得1,199美元的報銷,這將極大地爲公司的營業收入做出貢獻,併爲持續增長和提高市場估值鋪平道路。
The new DME partner's program offers favorable payment terms to Therma Bright which reflects the partner's confidence in Venowave, its market readiness, the robust HCPCS reimbursement set-up and the expected reimbursement timing. According to RXVantage "'Days to Pay' from service average 54 days during the miscellaneous HCPCS code period. But, they quickly 'normalize' to under 30 days after the HCPCS code is issued."
新的耐用醫療器械合作伙伴計劃爲Therma Bright提供了有利的付款條件,反映出合作伙伴對Venowave的信心,其市場準備,強大的HCPCS報銷設置以及預期的報銷時間。根據RXVantage的說法"在 HCPCS 代碼期間,' Days to Pay' 平均爲 54 天。但是,在發放 HCPCS 代碼後的 30 天內,他們很快就會'恢復正常'。"
"We are thrilled to welcome our Nationwide distribution partner to our team, and look forward to working with them closely on this program to demonstrate to their medical network the speed of reimbursement, as well as our efficient order and delivery process," shared Rob Fia, CEO of Therma Bright. "We expect the program to be successful, leading to a significant increase in Venowave orders on a monthly basis and accelerating our revenue growth."
"我們很高興歡迎我們的全國分銷夥伴加入我們的團隊,並期待與他們密切合作,以展示給他們的醫療網絡報銷的速度,以及我們高效的訂購和交付流程," Therma Bright 的首席執行官 Rob Fia 分享道。"我們預計該計劃將取得成功,每月Venowave訂單將大幅增加,並加快我們的營業收入增長。"
The Venowave VW5 is a series of compact, battery-operated peristaltic pumps that generate a wave-form motion. When worn below the knee, strapped firmly to the calf, the device results in compression of the calf and consequently an increased upward volumetric displacement of venous and lymph fluid. The 2-pair unit induces improved vascular and lymphatic flow in the lower limbs. Operating with a single rechargeable 1.5 V NiMh AA battery, this FDA-designated Durable Medical Equipment device enables users to receive treatment anywhere while remaining active. The Venowave VW5 assures it can withstand repeated use by successive patients.
Venowave VW5是一系列緊湊型、電池操作的蠕動泵,可以產生波形運動。當佩戴在膝蓋下方時,緊緊綁在小腿上,會導致小腿的壓縮,從而提高靜脈和淋巴液的向上體積位移。 2對裝置在下肢誘導改善血管和淋巴流動。使用單個可充電1.5 V NiMh AA電池,這款FDA指定的耐用醫療設備允許用戶在保持活躍的同時在任何地方接受治療。 Venowave VW5保證可經受連續患者的重複使用。
HCPCS Level II code E068 qualifies for reimbursement for ten (10) indications, including:
E068 HCPCS二級代碼適用於十(10)個指徵,包括:
- Prevention of deep vein thrombosis (DVT)
- Management of the symptoms of post-thrombotic syndrome (PTS)
- Prevention of primary thrombosis
- Treatment of lymphedema
- Diminishing post-operative pain and swelling
- Treatment of leg swelling due to vascular insufficiency
- Treatment of varicose veins
- Treatment of chronic venous insufficiency
- Enhancing blood circulation
- Treatment of intermittent claudication
- 預防深靜脈血栓形成(DVT)
- 管理後血栓性綜合症(PTS)症狀
- 預防原發性血栓形成
- 淋巴水腫的治療
- 緩解術後疼痛和腫脹
- 治療由於血管功能不足引起的腿部腫脹
- 靜脈曲張的治療
- 治療慢性靜脈功能不全
- 增強血液循環
- 間歇性跛行的治療
About Therma Bright Inc.
Therma Bright Inc.簡介:Therma Bright是一家開發商和合作夥伴,在各種領先的專有診斷和醫療器械技術方面致力於爲消費者和醫療專業人士提供質量卓越,創新的解決方案,以應對當今最重要的醫療和醫療保健挑戰。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。訪問:。
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席執行官
rfia@thermabright.com
rfia@thermabright.com
關注我們的Twitter賬號
FORWARD-LOOKING STATEMENTS
前瞻性聲明
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其監管服務提供商(如TSX Venture Exchange政策中所定義)對本新聞稿的充分性或準確性不承擔責任。